【24h】

Platelet-derived bio-products: Classification update, applications, concerns and new perspectives

机译:血小板衍生生物产品:分类更新,应用,顾虑和新的观点

获取原文
获取原文并翻译 | 示例
           

摘要

Platelet derived bio-products in the form of platelet rich plasma, plasma rich in growth factors, or plasma-free platelet releasates, are being studied worldwide with the aim of proving their efficacy in tissue regeneration within many different clinical areas, such as traumatology, maxillofacial surgery, ophthalmology, dermatology and otorhinolaryngology, amongst others. The current lack of consensus in the preparation method and application form, or in the quality assessment of each bio-product, precludes adequate interpretation of the relevance of reported clinical outcomes, and, while many in clinicians are very positive about them, many are sceptic. Relevant aspects of these products are considered to propose a classification nomenclature which would aid a comprehensive comparison of clinical outcomes of bio-products of the same characteristics. Finally, the uses of platelet-derived bio-products in in vitro culture (for cell therapy purposes) as a substitute of animal-origin sera, and other future perspectives of applications of platelet-derived bio-products are discussed.
机译:血小板衍生的生物产物以血小板富含血浆,富含生长因子的血浆或无等离子体血小板释放,目的是在许多不同临床区域(如创伤学)中的组织再生中的疗效颌面外科,眼科,皮肤病学和Otorhinolaryngology等。目前在制备方法和申请表中缺乏共识,或者在每个生物产品的质量评估中,排除了对报告临床结果的相关性的充分解释,虽然临床医生的许多人对他们非常积极,但许多人是怀疑论者。这些产品的相关方面被认为提出了分类命名,这将有助于全面比较同一特征的生物产物的临床结果。最后,讨论了体外培养中的血小板衍生的生物产物(用于细胞疗法目的)作为动物源血清的替代品,以及血小板衍生的生物产物的应用的其他未来观点。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号